The lactic dehydrogenase-to-albumin ratio predicts acute kidney injury in patients with intracerebral hemorrhage: a multicenter cohort study

乳酸脱氢酶与白蛋白比值可预测脑出血患者的急性肾损伤:一项多中心队列研究

阅读:1

Abstract

BACKGROUND: Acute kidney injury (AKI) is a common and serious complication in patients with intracerebral hemorrhage (ICH), contributing to poor clinical outcomes. The lactic dehydrogenase-to-albumin ratio (LAR) has emerged as a promising biomarker combining markers of cellular injury and systemic inflammation. However, its role in predicting AKI in ICH patients remains unexplored. OBJECTIVE: This study aims to evaluate the predictive value of LAR for AKI in ICH patients and assess its potential to enhance predictive models for AKI risk. METHODS: We conducted a retrospective, multicenter cohort study involving 6,465 patients with spontaneous ICH from three hospitals in China. LAR was calculated from routine laboratory values (lactic dehydrogenase and albumin), and its association with AKI was analyzed using logistic regression and receiver operating characteristic (ROC) curves. Subgroup analyses were performed to explore heterogeneity in the relationship between LAR and AKI. RESULTS: Higher LAR values were significantly associated with increased risk of AKI. Patients with LAR >5.61 had a higher odds ratio (OR 2.51, 95% CI 2.13-2.96) for developing AKI compared to those with lower LAR. A dose-response relationship was observed, with progressively higher AKI risk across LAR quartiles. Incorporating LAR into existing predictive models improved the accuracy from 0.73 to 0.76 (p < 0.001). Subgroup analysis revealed that age and hematoma volume influenced the strength of the LAR-AKI association. CONCLUSIONS: LAR is a reliable and cost-effective biomarker associated with AKI risk in ICH patients, with significant potential to enhance early detection and risk stratification; however, causality cannot be established due to the retrospective study design. Its incorporation into predictive models improves accuracy and provides a feasible tool for identifying high-risk patients. Further validation and long-term studies are needed to confirm its clinical utility across diverse populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。